SCHEMBL5341690

SCHEMBL5341690

CN(c1ccnc(NC2CCN(C(=O)OC(C)(C)C)CC2)n1)c1cc(-c2ccccc2)cc(=O)n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 5/20 0.48
▸ PRMT5 O14744 1/20 0.42
▸ ADORA2A P29274 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ SYK P43405 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ CKS1B P61024 1/20 0.40
▸ SKP1 P63208 1/20 0.40
▸ SKP2 Q13309 1/20 0.40
▸ GPR119 Q8TDV5 4/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ IDH1 O75874 1/20 0.40
▸ IDH2 P48735 1/20 0.40
▸ ACHE P22303 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5341694 0.88 MAPK14 (0.43) USP30MAPK14
SCHEMBL5914088 0.83 USP30 (0.46) USP30PRMT5ADORA2AMAPK14SYK
SCHEMBL5914261 0.83 USP30 (0.33) USP30MAPK14MAPK1
SCHEMBL5263546 0.80 USP30 (0.44) USP30PRMT5ADORA2AMAPK14ALDH1A1
SCHEMBL5267139 0.80 ACACB (0.41) USP30CKS1BSKP1SKP2
SCHEMBL5948116 0.80 USP30 (0.44) USP30PRMT5ADORA2AMAPK14SYK
SCHEMBL5913836 0.79 ALDH1A1 (0.48) USP30ADORA2AMAPK14SYKALDH1A1
SCHEMBL6420529 0.79 USP30 (0.45) USP30PRMT5ADORA2AMAPK14SYK
SCHEMBL5914172 0.77 MAPK14 (0.35) USP30MAPK14CKS1BSKP1SKP2
SCHEMBL3775260 0.75 USP30 (0.67) USP30ALDH1A1CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794135-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-06-13 — — EP claimed
WO-2006037117-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-04-06 — — WO claimed
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 — — US claimed
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069110-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP USP30 3267/4885PRMT5 2348/4885ADORA2A 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback